• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Colorectal cancer (first line) - cetuximab

Cetuximab for the first line treatment of metastatic colorectal cancer

Status:	History
Expected date of issue:	August 2009
Referral date:	December 2007
Wave:	15
Process:	STA
Topic area: Cancer Digestive system

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Peter Littlejohns
Technical Lead:	Helen Knight
Communications manager:	Alice Law
Project manager:	Jeremy Powell
Evidence review group:	West Midlands Health Technology Assessment Collaboration

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	08 April 2008
1st appraisal committee meeting:	03 September 2008
2nd appraisal committee meeting	04 November 2008
3rd appraisal committee meeting:	06 January 2009
4th appraisal committee meeting:	01 April 2009

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers / Sponsors Merck-Serono (cetuximab)   Patient / Carer Groups Beating Bowel Cancer Bowel Cancer UK Macmillan Cancer Relief   Professional Groups Association of Coloproctology of Great Britain and Ireland British Association of Surgical Oncology Cancer Research UK Royal College of Nursing Royal College of Pathologists Royal College of Physicians, Medical Oncology Joint Special Committee UK Oncology Nursing Society   Others Department of Health Islington PCT Nottinghamshire County PCT Welsh Assembly Government General Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland   Possible comparator manufacturer(s) Mayne Pharma plc (calcium folinate, fluorouracil, oxaliplatin)(declined to participate) Medac (UK) (disodium folinate, fluorouracil)(CA&U not returned, not participating) Merck-Serono (tegafur with uracil) Pfizer Ltd (irinotecan) Roche Diagnostics Roche Products Ltd (capecitabine) Sanofi-Aventis Ltd (oxaliplatin) Teva UK (calcium folinate)(CA&U not returned, not participating) Wockhardt UK (calcium folinate, fluorouracil)(CA&U not returned, not participating) Wyeth Pharmaceuticals (calcium levofolinate) (declined to participate)   Relevant research group Institute of Cancer Researchs   Evidence Review Group National Institute for Health Research Health Technology Assessment Programme West Midlands Health Technology Assessment Collaboration (WMHTAC)   Associated Guideline Groups National Collaborating Centre for Cancer   Associated Public Health Groups None

Top

 

Project history

Date Update 11 March 2008 Final scope re-issued due to anticipated change in licence 19 May 2008 First committee meeting delayed until 3 September 2008 20 November 2008 The Committee was not in a position to decide on a final appraisal determination because it needed further exploration of the consultation responses received. The Committee will reconvene to discuss this topic at its next meeting on 6 January 2009.

Top

 

Key documents

Colorectal cancer (first line) - cetuximab: final appraisal determination 01 June 2009 Colorectal cancer (first line) - cetuximab: appraisal consultation 2 29 January 2009 Colorectal cancer (first line) - cetuximab: letter to consultees and commentators about the outcome of the 4th November 2008 meeting 20 November 2008 Colorectal cancer (first line) - cetuximab: appraisal consultation 25 September 2008 Colorectal cancer (first line) - cetuximab: letter to consultees and commentators on delay to committee meeting 19 May 2008 Colorectal cancer - cetuximab: final scope (re-issued due to anticipated change in licence) 11 March 2008 Colorectal cancer - cetuximab: final scope 05 March 2008 Colorectal cancer - cetuximab: final matrix of consultees and commentators (list of stakeholders) 05 March 2008 Colorectal cancer - cetuximab: response to comments on the draft scope 05 March 2008 Colorectal cancer - cetuximab: response to comments on the provisional matrix 05 March 2008 Colorectal cancer - cetuximab: draft scope (pre-referral) 05 March 2008 Colorectal cancer - cetuximab: provisional matrix of consultees and commentators - pre- referral 05 March 2008

This page was last updated: 30 March 2010